Sepsis Clinical Trial
Official title:
Adrenal Cortical Function and Vitamin A Deficiency in Sepsis, Severe Sepsis and Septic Shock: Prospective Randomized, Double Blind Placebo Controlled Clinical Trials
The study involves the participant to receive a 250 mcg Cortrosyn (ACTH) Stimulation Test to
test the ability of the body to make Cortisol. If the body is not able to make large amount
of Cortisol (Delta Cortisol < 13 mg/dl) from the stimulation test, then the participant will
be given additional cortisol like medicine called Solumedrol or matching placebo.
If the body is able to make large amounts of Cortisol (> 13 mg/dl), then the participant
will receive daily shots of Vitamin A for 7 days or matching placebo.
If the participant does not respond to the stimulation test, and meets the criteria for
Cortisol deficiency (all 3 cortisol concentrations < 20 mg/dl), then he/she will screen
failed for the study and will be offered hydrocortisone as part of routine care by the
treating physician.
The eligible patients will have Sepsis, Severe Sepsis or Septic Shock. The potential subject
will be approached for the study participation and if agreed will sign an Inform Consent.
Patients unable to give consent, a waiver of consent was used. The participant to receive a
Cortrosyn Stimulation Test to test the ability of the body to make Cortisol. The Cortrosyn
Stimulation Test involves an injection into the vein in the arm. Two tablespoons of blood is
collected just before the injection of Cortrosyn (250 mcg of ACTH) and again 30 minutes and
60 minutes after the injection. The results of test are available about 3 hours after the
start of the test. Depending on the results of the test, subject will be either screen
failed or will either receive Solumedrol or Vitamin A. Also at the beginning of the study,
the amount of water in the subject's body will be measured using a machine called Impedance
Monitor.
If the body is not able to make large amount of Cortisol from the stimulation test (delta
increase in cortisol < 13 mg/dl), then the participant will be given additional cortisol
like medicine called Solumedrol (20 mg) by injection into a vein every 8 hours for 7 days or
matching placebo.
If the body is able to make large amounts of Cortisol (delta cortisol response > 13 mg/dL),
then the participant will receive daily shots of Vitamin A or matching placebo for 7 days by
injection into arm muscle. After 1, 3, 8 and 14 days of the study, a blood draw will
performed to measure the amount of Vitamin A in the blood. Also, the urine will be collected
to measure Vitamin A levels on day 1, 2, 3, 8 and 14. The ACTH stimulation test was repeated
on Day 8.
The total amount of blood drawn for the study will be about 18 tablespoons.
If the participant does not respond to the stimulation test, and meets the criteria for
Cortisol deficiency (All cortisol concentrations < 20 mg/dl) , then he/she will screen
failed for the study and will be offered 100 mg of hydrocortisone treatment (100 mg IV every
8 hours) as part of routine care by the treating physician.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |